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background: Bococizumab (BOCO) is a humanized monoclonal antibody that binds to proprotein convertase subtilisin/kexin type 9 and is a 
therapeutic approach for reducing LDL-C levels in hypercholesterolemic (HC) patients. The objective of this study was to evaluate various BOCO 
subcutaneous (SC) doses administered every 2 weeks (Q14d) or monthly (Q28d).
methods: This was a 24-week, multicenter, randomized, double-blind, placebo-controlled trial in statin-treated subjects aged ≥18 yrs with a 
diagnosis of HC and LDL-C ≥80 mg/dL. Subjects were randomized to Q14d SC placebo, BOCO 50 mg, 100 mg, or 150 mg; or Q28d placebo, BOCO 
200 mg or 300 mg. Doses were reduced if LDL-C readings were ≤25 mg/dL. The primary analysis was the placebo-adjusted treatment difference for 
the change from baseline in LDL-C at Week 12.
results: BOCO significantly reduced LDL-C across all doses (Table). Up to 44% of subjects in the BOCO groups had their dose reduced. Model-
based simulation that assumed no dose reductions predicted greater LDL-C lowering than the primary endpoint, which included subjects having 
doses reduced. AEs were similar across placebo and BOCO groups. Few subjects discontinued treatment due to treatment-related AEs (Table).
conclusions: BOCO 150 mg Q14d significantly reduced LDL-C by 53 mg/dL vs. placebo at Week 12, inclusive of the protocol-directed dose 
reductions in 35% of subjects. Modeling predicted greater LDL-C reduction in absence of BOCO dose reduction. The Q14d regimen is being 
evaluated in larger trials.
Placebo 
Q14d
(n=49)
BOCO 
50 mg Q14d 
(n=50)
BOCO 100 mg 
Q14d (n=51)
BOCO 150 mg 
Q14d (n=49)
Placebo 
Q28d
(n=51)
BOCO 200 
mg Q28d
(n=50)
BOCO 300 mg 
Q28d
(n=51)
Baseline LDL-C, mg/dL
108.7 ± 
31.5
107.9 ± 
20.2
113.4 ± 25.7 105.8 ± 18.0
118.8 ± 
44.8
105.7 ± 23.2 104.7 ± 22.1
Subjects with dose reduction 0 0 16% 35% 0 44% 39%
Absolute change from baseline in LDL-C at Week 12, mg/dL
−2.8 ± 
29.2
−35.4 ± 
26.6
−52.3 ± 31.3 −54.2 ± 27.0
−1.3 ± 
37.2
−21.3 ± 28.0 −38.3 ± 41.3
Adjusted change from baseline in LDL-C at Week 12, versus placebo,* 
mg/dL
---
−34.3
(−45.1, 
−23.5)
−45.1
(−55.9, −34.2)
−53.4
(−64.1, −42.7)
---
−27.6
(−40.5, 
−14.7)
−44.9
(−57.7, 
−32.1)
Model predicted placebo-adjusted LDL-C change from baseline at 
Week 12 assuming no dose reduction,** mg/dL
---
−36.3
(−42.0, 
−30.3)
−60.6
(−67.1, −55.5)
−72.1
(−77.5, −67.0)
---
−40.3
(−47.2, 
−34.3)
−55.7
(−61.6, 
−48.0)
Subjects with treatment-related SAEs 0 0 0 2% 0 0 0
Discontinuation of treatment due to treatment-related AEs 0 2% 0 8% 0 0 4%
Values are mean ± SD, %, or n=number treated, also see * and ** below. BOCO, bococizumab; LDL-C, low-density lipoprotein cholesterol; AE, adverse event; SAE, serious AE.
*Mean (95% confidence interval), calculated using a repeated measures model for longitudinal data.
**Population PK/PD model predictions of median absolute LDL-C change from baseline (2.5th and 97.5th percentile) for 100 trials (50 subjects/arm) using baseline demographics 
observed in this study.
